Browsing by Subject "lung cancer"
Now showing 1 - 20 of 20
Results Per Page
Sort Options
Item Effect of chemotherapy on pulmonary epithelial permeability in lung cancer(2000) Sayit E.; Aktoǧu S.; Ertay T.; Çapa G.; Erkmen G.; Özbilek E.; Büyükşirin M.; Durak H.The aim of this study is to investigate the effect of one-course chemotherapy on the pulmonary epithelial permeability. Eighteen patients (18 male; mean age: 59 ± 10 years) with lung cancer (11 non-small cell, 7 small cell) inhaled 40 mCi (1,480 MBq) 99mTc-diethylenetriaminepentaacetic acid (DTPA). Thirty images of 1-min duration were acquired from posterior projection. The first 7 min of the decay-corrected time activity curves were used to calculate lung clearance half-time. Clearance half-times of 99mTc-DTPA from the peripheral regions of the lungs were 42 ± 19 min before and 56 ± 34 min after chemotherapy (p = 0.009); from the central regions, clearance half-times were 112 ± 94 min before and 160 ± 125 min after chemotherapy (p = 0.005). This decrease in clearance rate might be related to decreasing mucociliary clearance rate due to the toxic effect of the chemotherapy regimen on cilia movement and/or mucus structure. 99mTc-DTPA radioaerosol study can be used to monitor the toxic effects of chemotherapy on the pulmonary epithelium and possibly on mucociliary function. (C) 2000 Elsevier Science Inc.Item Patterns of Care for Lung Cancer in Radiation Oncology Departments of Turkey(2008) Demiral A.N.; Alicikus Z.A.; Işil Ugur V.; Karadogan I.; Yöney A.; Andrieu M.N.; Yalman D.; Pak Y.; Aksu G.; Özyigit G.; Özkan L.; Kilçiksiz S.; Koca S.; Çaloǧlu M.; Yavuz A.A.; Başak Çaǧlar H.; Beyzadeoǧlu M.; Iǧdem S.; Serin M.; Kaplan B.; Koç M.; Korkmaz E.; Karakoyun-Çelik O.; Dinçer S.; Kinay M.Purpose: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. Methods and Materials: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. Results: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were "≥ IB" disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. Conclusion: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach. © 2008 Elsevier Inc. All rights reserved.Item High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients(Elsevier Ireland Ltd, 2008) Ozkok S.; Karakoyun-Celik O.; Goksel T.; Mogulkoc N.; Yalman D.; Gok G.; Bolukbasi Y.The aim of this study was to evaluate the symptomatic and endoscopic responses as well as the toxicities in 158 patients with endobronchial lung cancer treated with high dose rate endobronchial brachytherapy (HDR-EB). Forty-three patients with stage III NSCLC were treated with 60 Gy external beam radiotherapy (ERT) and three applications of 5 Gy each of HDR-EB (group A). Seventy-four patients who did not receive previous RT were treated with 30 Gy ERT and two applications of 7.5 Gy HDR-EB with palliative intent (group B). Forty-one patients with recurrent tumor who were irradiated previously were treated with three applications of 7.5 Gy HDR-EB, with palliative intent (group C). In group A, bronchoscopic complete (CR) and overall response rates (ORR) were 67% and 86%, respectively. Symptomatic improvement was obtained in 58% of patients with cough, 77% of patients with dyspnea and 100% of patients with hemoptysis. Two and 5-year survival rates were 25.5% and 9.5%, respectively and the median survival time (MST) was 11 months. In group B, the bronchoscopic CR and ORR were 39% and 77%, respectively and 28% and 72% in group C. The symptomatic response rates were 57% and 55% for cough, 90% and 78% for dyspnea and 94% and 77% for hemoptysis, with a MST of 7 and 6 months in Groups B and C, respectively. Eighteen patients (11%) died of fatal hemoptysis (FH) with the median time to this event of 7 months. Treatment intent (p < 0.001), total BED (p < 0.001) and the number of HDR-EB fractions (p < 0.001) were significant prognostic factors for FH. HDR-EB provides effective palliation in relieving the symptoms of patients with endobronchial lung cancer, however, there is a risk of developing FH that is associated with a high BED and multiple HDR-EB applications. © 2008 Elsevier Ireland Ltd. All rights reserved.Item Factors affecting the interval from diagnosis to treatment in patients with lung cancer(Il Pensiero Scientifico Editore s.r.l., 2009) Yaman N.; Ozgen A.; Celik P.; Ozyurt B.C.; Nese N.; Coskun A.S.; Yorgancioglu A.Aims and background. We aimed to investigate the factors affecting the interval from the beginning of the symptoms until diagnosis and treatment in patients with lung cancer. Methods. Records of 119 lung cancer patients diagnosed in our pulmonary diseases clinic between 2004 and 2006 were evaluated retrospectively. Demographic data, histopathological tumor type, TNM stage, ECOG performance status, presence of endobronchial lesions, and radiological localization of the tumor were determined. Intervals from the first symptom to contacting a doctor, to diagnosis and to treatment were calculated. The interval from first admission to a clinic and referral to a chest physician was also calculated. Results. Of 119 patients, 74% were diagnosed as non-small cell and 26% were as small cell lung cancer. Forty-eight percent of the patients were at stage 3B and 36% were at stage 4. ECOG performance status was 0 in 6%, 1 in 52%, 2 in 36%, 3 in 3%, and 4 in 2%. Endobronchial lesions were observed in 50% of the patients, and the lesions had a central radiological localization in 59%. Fifty-four percent of the patients presented to a chest physician first. Patients who first presented to an internal medicine clinic were referred to our pulmonary disease clinic significantly later than those who presented to other clinics (P = 0.005). The median period from the beginning of the symptoms until contacting a doctor was 35 days (range, 1-387), until diagnosis was 49 days (range, 12-396), and until beginning the treatment was 57 (range, 9-397) days. The presence of endobronchial lesions, radiological localization, TNM stage and ECOG performance status were not found to be related to the intervals from the first symptom to presentation to a doctor, to diagnosis or to the beginning of the treatment. Conclusions. Lung cancer patients consult a doctor after a relatively long symptomatic period. Patient delays may be shortened by increasing the awareness of patients about lung cancer symptoms. Diagnostic procedures should be performed more rapidly to shorten doctor delays.Item Evaluation of physians, patients, relatives and society of opinions on the told lung cancer diagnosis; [Hekimlerin, hasta yakınlarının ve toplumun akciğer kanseri tanısının söylenmesine ilişkin görüşlerinin değerlendirilmesi](Ankara University, 2017) Datli U.; Çelik P.; Havlucu Y.; Göktalay T.; Şakar Coşkun A.; Yorgancioğlu A.A.Introduction: In our country, this is usually done by patient relatives. In this study, we aimed to investigate the thought of doctors who done the diagnosis, doctors who arrange the treatment, first degree relatives of patients with lung cancer, and population as a control. Materials and Methods: 310 subjects (100 doctors, 110 first degree realtives of patients, and 100 subjects as a control) were included to the study. The mean age was 39.77 ± 11.44 years and there was 170 females. 46% of doctors were giving cancer treatment (chemotheraphy/radiotheraphy). Results: 84.5% of subjects were answered the question (Do you want to know the diagnosis of lung cancer if you are lung cancer?) as "yes" and the answers were not different between groups (p> 0.05). 72 of doctors were giving information about diagnosis of patients. This ratio was 89.1% in doctors who arrange lung cancer treatment whereas it was 57.4% in doctors who do not arrange cancer treatment. The percent age of learning of diagnosis of lung cancer throughout the time in doctors, population, and patient's relatives were 19%, 34%, and 59% respectively (p< 0.05). Information about quality of life was more important in relatives of patients (87%) than population (65%) and doctors (63%) (p< 0.05). Quality of life was more important for doctors who arrange lung cancer treatment (76.7)% than doctors who did not (48.8%) (p< 0.05). Patients who were more children wanted to stay with their family at end stage of disease (p< 0.05). Conclusion: According to this study we think that doctors should say the diagnosis of lung cancer in the form of they understand, inform the patients and relatives about treatment, and quality of life and this can increase patient trust to doctor and compliance of patients to the treatment. © 2017, Ankara University. All rights reserved.Item The assessment of the effect of changes in lung cancer follow-up period on the quality of life using EQ-5D questionnaire and follow data (AKAYAK-1 multicenter project); [Akciğer Kanserli Hastalarda İzlem Sürecindeki Değişikliklerin Yaşam Kalitesine Etkisinin EQ-5D Ölçeği ve Takip Sonuçları ile Değerlendirilmesi (AKAYAK-1 Çok Merkezli Proje)](UHOD - Uluslararasi Hematoloji Onkoloji Dergisi, 2018) Erbaycu A.E.; Goksel T.; Eser E.; Gursul K.K.; Basarik B.; Oz A.; Celik P.; Ediz E.C.; Hatipoglu O.; Yayla B.A.; Baser S.; Baydur H.The EURO-QOL (EQ-5D), a generic quality of life measure, is a self-report scale. The aim was to study the reliability, validity and feasibility of the Turkish version of the EQ-5D as an instrument to evaluate quality of life in lung cancer patients in Turkish society. A prospective cohort study carried out within the framework of the multicenter Lung Cancer Association Project which was conducted in collaboration with Turkish Thoracic Society, Lung and Pleural Malignancies working group and Health and Quality of Life Society. A total of 266 patients were included in the study with a mean age of 61.3 years. 75,9% of the patients had chemotherapy alone; 9% received sequential chemotherapy and radiotherapy, 8,6% were given concurrent chemotherapy and radiotherapy, and 6,4% of them received radical radiotherapy alone. EQ-5D score measures at the moment of diagnosis were found to be moderately reliable while measures at the 3rd chemotherapy cycle, 5th chemotherapy cycle and after the radiotherapy were highly reliable. The items of the EQ-5D were found to be consistent among themselves. EQ-5D Visual Analogue Scale scores at diagnosis, the 3rd cycle, the 5th cycle and following radiotherapy were assessed to be correlated with each other. EQ-5D scale was found to be valid as it meets the conditions of 6 fit indices in our study design. The psychometric properties of the Turkish version of the EQ-5D questionnaire is a valid and reliable scale for patients with lung cancer in Turkey and it can be safely used in clinical practices. © 2018, UHOD - Uluslararasi Hematoloji Onkoloji Dergisi. All rights reserved.Item Antibiotic treatment outcomes in community-acquired pneumonia(Turkiye Klinikleri Journal of Medical Sciences, 2018) Çilli A.; Sayiner A.; Çelenk B.; Şakar Coşkun A.; Kilinç O.; Hazar A.; Aktaş Samur A.; Taşbakan S.; Waterer G.W.; Havlucu Y.; Kiliç Ö.; Tokgöz F.; Bilge U.Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a β-lactam, β-lactam and macrolide combination, or a fluoroquinolone. Materials and methods: This prospective cohort study was performed using standardized web-based database sheets from January 2009 to September 2013 in nine tertiary care hospitals in Turkey. Results: Six hundred and twenty-one consecutive patients were enrolled. A pathogen was identified in 78 (12.6%) patients. The most frequently isolated bacteria were S. pneumoniae (21.8%) and P. aeruginosa (19.2%). The clinical cure rate and length of stay were not different among patients treated with β-lactam, β-lactam and macrolide combination, and fluoroquinolone. Forty-seven patients (9.2%) died during the hospitalization period. There was no difference in survival among the three treatment groups. Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between β-lactam, β-lactam and macrolide combination, and fluoroquinolone regimens. © TÜBİTAK.Item The effect of inhaled corticosteroids in the outcomes of community-acquired pneumonia: ICCAP study (TURKCAP Database)(Blackwell Publishing Ltd, 2020) Baha A.; Kokturk N.; Bahcecioglu S.N.; Yapar D.; Aksakal N.; Gündüz C.; Tasbakan S.; Sayiner A.; Coskun A.S.; Durmaz F.; Cilli A.; Celenk B.; Kılınc O.; Salman S.; Hazar A.; Tokgoz F.Objective: We aimed to investigate the effect of inhaled corticosteroids (ICS) in the outcomes of community-acquired pneumonia (CAP), as well as to determine if ICS usage is exist among the risk factors for mortality in those patients. Materials and Methods: In this retrospective cross-sectional multicentre study, 1069 hospitalised CAP patients were investigated using CAP Database of Turkish Thoracic Society (TURKCAP Database). The patients were divided into two groups, depending on their ICS use. The data were analysed by appropriate statistical methods. Results: 172 (75.8%) of the 227 patients who were on ICS had COPD and 37 (16.3%) had asthma. There were fewer patients with fever among ICS-users compared to non-ICS users (P = 0.013), and less muscle pain (P = 0.015) and fewer GIS symptoms (P = 0.022). No statistically significant difference was found between ICS use/ type of ICS and the duration of hospitalisation (P = 0.286). The multivariate regression analysis showed that patients using ICS had lower body temperature and, less crackles/bronchial sound. In the multivariate logistic regression model lung cancer (OR: 6.75), glucose (OR: 1.01) and CURB-65 (OR: 1.72) were significantly associated with mortality in the CAP patients. ICS usage were not found to be associated with mortality. Conclusion: The use of ICS by the patients with CAP admitted to the hospital is not independently related with any radiological pattern, hospitalisation duration and mortality. ICS usage may diminish fever response and may suppress the findings of crackles and/or bronchial sounds. This needs further confirmation. © 2020 John Wiley & Sons LtdItem Essential Oils from Vitex agnus castus L. Leaves Induces Caspase-Dependent Apoptosis of Human Multidrug-Resistant Lung Carcinoma Cells through Intrinsic and Extrinsic Pathways(Routledge, 2020) Ilhan S.Essential oil (EO) fractions of plants are complex mixtures of volatile compounds with broad-spectrum biological properties. In the current study, the EO content of Vitex agnus castus L. (VAC) leaves growing in the Aegean region of Turkey was extracted and identified. Then, VAC EOs were investigated for their potential antioxidant, cytotoxic and apoptotic effects in human H69AR multi-drug resistant cancer cells. EOs were isolated by hydrodistillation and chemical composition was determined by GC-MS. Cell viability was assessed via MTT and trypan blue assays. Antioxidant activity was evaluated by measuring the total antioxidant activity and free radical scavenging activity. Apoptosis was evaluated via DNA fragmentation and caspase 3/7 activity assays. Changes in the levels of apoptotic genes were determined by RT-qPCR. The results indicated strong antioxidant activity and cytotoxic effect on H69AR cancer cells but not on HEK-293 human normal cells indicating the tumor-specific effect. VAC EOs induced caspase 3/7 activation and apoptosis through triggering both extrinsic- and intrinsic-pathways by modulating Bcl-2, Bcl-XL, Bax, Bad, FADD, Caspase-8, Caspase-9, TRAIL R1/DR4 and TRAIL R2/DR5. This study revealed that VAC EOs may be a promising candidate in the development of novel therapeutic agents for multi-drug resistant lung cancer treatment. © 2020 Taylor & Francis Group, LLC.Item COVID-19 pandemic and the global perspective of turkish thoracic society(AVES, 2020) Köktürk N.; İtil B.O.; Altınışık G.; Adıgüzel N.; Akgün M.; Akyıldız L.; Altın S.; Arıkan H.; Ateş G.; Ay P.; Aykaç N.; Babayiğit C.; Bostan P.; Cinel G.; Çalışır H.C.; Çelik P.; Çetinkaya P.D.; Dağlı E.; Demir A.U.; Demir C.; Dikensoy Ö.; Edis E.Ç.; Elbek O.; Erdinç M.; Ergan B.; Eyüboğlu A.F.Ö.; Gemicioğlu B.; Göksel T.; Gülhan E.; Gültekin Ö.; Gürkan C.G.; Gürgün A.; Havlucu Y.; Başoğlu O.K.; Karakurt S.; Karakurt Z.; Kılınç O.; Kocabaş A.; Kul S.; Müsellim B.; Naycı S.; Özkan M.; Pınarer Ö.; Saltürk C.; Sandal A.; Sayıner A.; Şen E.; Şimşek G.Ö.; Karadağ B.T.; Akyıl F.T.; Töreyin Z.N.; Uçan E.S.; Küçük F.Ç.U.; Varol A.; Yasin Y.; Yıldız T.; Arzu Yorgancıoğlu A.; Bayram H.It has been more than 3 months now since the first case of COVID-19 was reported in Turkey. Globally, the number of confirmed cases and deaths reached 9,653,048 and 491,128 respectively, as reported by 216 countries by June 27, 2020. Turkey had 1,396 new cases, 194,511 total cases, and 5,065 deaths by the same date. From the first case until today, the Turkish Thoracic Society (TTS) has been very proactive in educating doctors, increasing public awareness, undertaking academic studies, and assisting with public health policies. In the present report, social, academic, and management perspectives of the pandemic are presented under appropriate subtitles. During this critical public health crisis, TTS has once again demonstrated its readiness and constructive stance by supporting public health, healthcare workers, and the environment. This review summarizes the perspective of TTS on each aspect of the COVID-19 pandemic and casts light on its contributions. © 2020 by Turkish Thoracic Society.Item A rare complication of video-assisted thoracoscopic surgery: Lung herniation retrospective case series of three patients and review of the literature(Termedia Publishing House Ltd., 2020) Batıhan G.; Yaldız D.; Ceylan K.C.Introduction: Lung herniation is defined as a protrusion of the lung parenchyma with its pleura through the intercostal space. It is a rare condition and usually occurs after thoracic trauma and surgical interventions. A few cases of lung herniations have been reported after video-assisted thoracoscopic surgery (VATS) but only two cases have been reported after VATS lobectomy. Aim: The VATS procedure has become the dominant method of lung cancer surgery, but there is no case series about the complications of lung herniation in the literature. We aim to define some risk factors and possible ways of prevention of lung herniation after VATS resection. Material and methods: This study retrospectively analyses 650 (550 anatomic, 100 non-anatomic sublobar resections) patients who underwent lung resections for lung cancer in our department between 2012 and 2018. We detected lung herniation in 3 patients after VATS resection. Results: Asymptomatic lung hernias may be managed by close observation but because of the risk of incarceration of the pulmonary parenchyma, surgery is often necessary. The main steps of treatment involve: identification of the hernia, freeing of all adhesions, reduction of the lung tissue back into the thoracic cavity and repairing the defect of the chest wall. Conclusions: By this retrospective case series, we defined some patient-related and surgeon-related risk factors and some basic recommendations for prevention of this complication. © 2020 Termedia Publishing House Ltd.. All rights reserved.Item Thymoquinone glucuronide conjugated magnetic nanoparticle for bimo-dal imaging and treatment of cancer as a novel theranostic platform(Bentham Science Publishers, 2021) İnce İ.; Müftüler Z.B.; Medine E.İ.; Güldü Ö.K.; Takan G.; Ergönül A.; Parlak Y.; Yıldırım Y.; Çakar B.; Bilgin E.S.; Aras Ö.; Göker E.; Ünak P.Background: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancer-ous cells without damaging the surrounding healthy tissues. Objective: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide thera-py. Methods: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rab-bits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6–7-week-old nude mice utilized with bioluminescence imaging. Results: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively. Conclusion: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers. © 2021 Bentham Science Publishers.Item Clean air for healthy lungs - An urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines(European Respiratory Society, 2021) Andersen Z.J.; Gehring U.; De Matteis S.; Melen E.; Vicedo-Cabrera A.M.; Katsouyanni K.; Yorgancioglu A.; Ulrik C.S.; Medina S.; Hansen K.; Powell P.; Ward B.; Hoffmann B.[No abstract available]Item Cryptosporidium spp. During chemotherapy: A cross-sectional study of 94 patients with malignant solid tumor(King Faisal Specialist Hospital and Research Centre, 2021) Karabey M.; Can H.; Öner T.Ö.; Döşkaya M.; Alak S.E.; Döşkaya A.D.; Karakavuk M.; Köseoğlu A.E.; Ün C.; Gürüz A.Y.; Alacacıoğlu A.; Pektaş B.; Gül A.; Kaya S.; Gökmen A.A.BACKGROUND: Cryptosporidium spp. is a protozoan parasite that infects many vertebrate animals, including humans. Since Cryptosporidium spp. can cause chronic life-threatening diarrhea and severe malabsorption in immunocompromised patients, we investigated the prevalence of this parasite among patients undergoing chemotherapy for malignant solid tumors. OBJECTIVE: Investigate the prevalence of Cryptosporidium spp. in stool samples. DESIGN: Cross-sectional. SETTING: Tertiary care. PATIENTS AND METHODS: Stool samples were collected from adult patients with malignant solid tumors receiving chemotherapy and diarrhea. Cryptosporidium spp. prevalence was determined using Ziehl-Neelsen staining, ELISA, and real-time PCR targeting of the COWP gene. MAIN OUTCOME MEASURE: The prevalence of Cryptosporidium spp. in patients undergoing chemotherapy for malignant solid tumors. SAMPLE SIZE: 94 RESULTS: The prevalence was 2.1% (2/94), 5.3% (5/94), and 5.3% (5/94) as detected by Ziehl-Neelsen staining, real-time PCR and ELISA, respectively. The prevalence reached 8.5% (8/94) using all results obtained from the three methods. Among eight positive stool samples, four were positive by at least two different methods (Ziehl-Neelsen staining-ELISA or ELISA-real-time PCR) whereas the remaining four were positive by either ELISA or real-time PCR. CONCLUSION: These findings show the risk of cryptosporidiosis in cancer patients and the necessity to use at least two diagnostic methods during the diagnosis of cryptosporidiosis to reach more accurate and trustworthy results. LIMITATIONS: Further studies with a larger sample size are recommended. Copyright: Copyright © 2021, Annals of Saudi Medicine, Saudi Arabia. This is an open access article under the Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International License (CC BY-NC-ND). The details of which can be accessed at http://creativecommons. org/licenses/bync-nd/4.0/Item Pulmonary nodules in children; [Çocuklarda pulmoner nodüller](Ankara University, 2022) Yüksel H.; Tongal S.N.Clinicians and radiologist nowadays frequently encounter pulmonary nodules in children, thanks to the widespread use of computed tomography (CT) thorax. Most pulmonary nodules are benign; however, a small number of pulmonary nodules indicate pulmonary malignancy in children, requiring prompt diagnosis and treatment. Incidentally diagnosed pulmonary nodules are common and naturally cause anxiety in families and in clinicians, leading to successive examinations. For this reason, the creation of algorithms for the diagnosis and follow-up of pulmonary nodules, and the definition of advanced imaging requirements will facilitate the management of these patients; early diagnosis and treatment will be provided in patients with malignant tumors, and unnecessary interventions will be minimized in patients with benign nodules. This review is designed to explore current information on nodule definition, diagnostic evaluation, and management in the pediatric age group based on previously obtained data. © 2022 by Tuberculosis and Thorax.Item Biphasic split-bolus injection protocol for routine contrast-enhanced chest CT: comparison with conventional early-phase single bolus technique(British Institute of Radiology, 2022) Kul M.; Öz D.K.; Coruh A.G.; Ateş F.Ö.; Gülpinar B.; Uzun Ç.; Atasoy K.Objectives: To present a routine contrast-enhanced chest CT protocol with a split-bolus injection technique achieving combined early- and delayed phase images with a single aquisition, and to compare this technique with a conventional early-phase single-bolus chest CT protocol we formerly used at our institution, in terms of attenuation of great thoracic vessels, pleura, included hepatic and portal venous enhancement, contrast-related artifacts, and image quality. Methods: A total of 202 patients, who underwent routine contrast-enhanced chest CT examination aquired with either conventional early-phase single-bolus technique (group A,n = 102) or biphasic split-bolus protocol (group B,n = 100), were retrospectively included. Attenuation measurements were made by two radiologists independently on mediastinal window settings using a circular ROI at the following sites: main pulmonary artery (PA) at its bifurcation level, thoracal aorta (TA) at the level of MPA bifurcation,portal vein (PV) at porta hepatis, left and right hepatic lobe, and if present, thickened pleura (>2 mm) at the level with the most intense enhancement. Respective normalized enhancement values were also calculated. Contrast-related artifacts were graded and qualitative evaluation of mediastinal lymph nodes was performed by both reviewers independently. Background noise was measured and contrast-to-noise ratios (CNRs) of the liver and TA were calculated. Results: While enhancement of thoracic vessels and normalised MPA enhancement did not differ significantly between both groups (p > 0.05), enhancement and normalised enhancement of pleura, liver parenchyma and PV was significantly greater in group B (p < 0.001). Perivenous artifacts limiting evaluation were less frequent in group B than in A and mediastinal lymph nodes were judged to be evaluated worse in group A than in group B with an excellent agreement between both observers. No significant difference was detected in CNRTA (p = 0.633), whereas CNR liver was higher in group B (p < 0.001). Conclusion: Our split-bolus chest CT injection protocol enables simultaneous enhancement for both vascular structures and soft tissues, and thus, might raise diagnostic confidence without the need of multiple acquisitions. Advances in knowledge: We think that this CT protocol might also be a promising alternative in lung cancer staging, where combined contrast-enhanced CT of the chest and abdomen is indicated. We therefore suggest to further evaluate its diagnostic utility in this setting, in particular in comparison with a late delayed chest-upper abdominal CT imaging protocol. © 2022 The Authors.Item Examining the relationship between symptoms watched in lung cancer patients and illness perception(Pakistan Medical Association, 2022) Ugur O.; Karadag E.; Mert H.; Sahin C.K.; Gurel T.Y.; Karakus H.S.Objective: To examine the relationship between the symptom experience of lung cancer patients and their illness perception of the disease. Methods: The descriptive and cross-sectional study was conducted from April to September 2015 at the Chemotherapy Treatment Centre of the Medicine Chest Diseases Clinic at the Ege University, Izmir, Turkey, and comprised lung cancer patients of either gender aged >18 years. Data was collected using a predesigned Patient Questionnaire as well as the standard Lung Cancer Symptom Scale, Illness Perception Questionnaire and Karnofsky Performance Scale. The patients' sociodemographic characteristics and data on their illness, the symptoms they experienced and the numerical and percentage distribution of the items on the illness perception scale, mean and standard deviation values were examined. Pearson Correlation analysis was used to examine the correlation between illness perception and Karnofsky Performance Scale scores and other variables. Results: Of the 105 patients, 86(81.9%) were males, 86(81.9%) were married, 49(46.7%) were elementary school graduates, 101(96.2%) were unemployed, and 95(90.5%) were receiving chemotherapy. The overall mean age of the sample was 61.43±8.24 years, the period since diagnosis was 11.38±17.84 months, and the duration of chemotherapy was 4.28±2.37 months. The mean symptom burden score was 22.75±10.85 and the Lung Cancer Symptom Scale score was 22.75±10.85. The mean score of the type of illness domain was 5.53±2.12. The overall mean global quality of life score was 64.30±12.60. Conclusions: As the symptom burden experienced by the lung cancer patients increased, their perception of the illness became more negative, and the longer the cyclical periods and the period of diagnosis, the patients' control over their illness decreased. © 2022 Pakistan Medical Association. All rights reserved.Item Lung cancer from suspicion to treatment: An indicator of healthcare access in Turkey(Elsevier Ltd, 2023) Kızılırmak D.; Yılmaz Kaya Z.; Gökçimen G.; Havlucu Y.; Cengiz Özyurt B.; Gündoğuş B.; Esendağlı D.; Serez Kaya B.; Yılmam İ.; Aydemir Y.; Çolak M.; Afşin E.; Çetin N.; İdikut A.; Değirmenci C.; Oral Tapan Ö.; Gündüz Gürkan C.; Kocatürk C.İ.; Ömeroğlu Şimşek G.; Kalafat C.E.; Özgün Niksarlıoğlu E.Y.; Ergün Serdaroğlu M.; Karcıoğlu O.; Özyurt S.; Karahacıoğlu Madran E.; Yaprak Bayrak B.; Alasgarova Z.; Baydar Toprak O.; Yılmazel Uçar E.; Topal B.N.; Argun Barış S.; Guliyev E.; Güzel E.; Küçük S.; Ocaklı B.; Baran Ketencioğlu B.; Selçuk N.T.; Sarı Akyüz M.; Sercan Özgür E.; Yetkin N.A.; Çetinkaya P.D.; Deniz P.P.; Atlı S.; Çetindoğan H.; Karakaş F.G.; Yılmaz E.S.; Ergün D.; Ergün R.; Tulay C.M.; Ünsal M.; Demirkaya İ.; Marım F.; Kaya İ.; Demirdöğen E.; Görek Dilektaşlı A.; Ursavaş A.; Çelik P.Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Before beginning lung cancer treatment, it is necessary to complete procedures such as suspecting lung cancer, obtaining a pathologic diagnosis, and staging. This study aimed to investigate the processes from suspicion of lung cancer to diagnosis, staging, and treatment initiation. Methods: The study was designed as a multicenter and cross-sectional study. Patients with lung cancer from various health institutions located in all geographic regions of Turkey were included in the study. The sociodemographic and clinical characteristics of the patients, the characteristics of the health institutions and geographic regions, and other variables of the lung cancer process were recorded. The time from suspicion of lung cancer to pathologic diagnosis, radiologic staging, and treatment initiation, as well as influencing factors, were investigated. Results: The study included 1410 patients from 29 different medical centers. The mean time from the initial suspicion of lung cancer to the pathologic diagnosis was 48.0 ± 52.6 days, 39.0 ± 52.7 days for radiologic staging, and 74.9 ± 65.5 days for treatment initiation. The residential areas with the most suspected lung cancer cases were highly developed socioeconomic zones. Primary healthcare services accounted for only 0.4% of patients with suspected lung cancer. The time to pathologic diagnosis was longer in the Marmara region, and the wait time for staging and treatment initiation was longer in Eastern and Southeastern Anatolia. Patients who presented to chest disease referral hospitals with peripheral lesions, those with early-stage disease, and those who were diagnosed surgically had significantly longer wait times. Conclusion: The time between pathologic diagnosis, staging, and treatment initiation in lung cancer was longer than expected. Increasing the role of primary healthcare services and distributing socioeconomic resources more equally will contribute to shortening the time to diagnosis and improve treatment processes for lung cancer. © 2023 Elsevier LtdItem Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening(European Respiratory Society, 2023) Ward B.; Vašáková M.K.; Cordeiro C.R.; Yorgancioğlu A.; Chorostowska-Wynimko J.; Blum T.G.; Kauczor H.-U.; Samarzija M.; Henschke C.; Wheelock C.; Grigg J.; Andersen Z.J.; Koblížek V.; Májek O.; Odemyr M.; Powell P.; Seijo L.M.[No abstract available]Item The performance of Khorana risk score for prediction of venous thromboembolism in patients with lung cancer: A retrospective cohort study; [Akciğer kanserli hastalarda venöz tromboembolizmin tahmininde Khorana risk skorunun performansı: Retrospektif kohort çalışma](Ankara University, 2024) Kizilirmak D.; Fidan U.; Havlucu Y.Introduction: Cancer-related venous thromboembolism is one of the leading causes of mortality and morbidity in cancer patients. Lung cancer is the second most common cancer in the world and is closely related to venous thromboembolism. Venous thromboembolism affects survival in patients with cancer and it is important to be able to predict the possibility of thrombosis in patients with cancer. It was aimed to evaluate the predictive performance of the Khorana risk score in patients with lung cancer. Materials and Methods: The medical data of the patients followed up with lung cancer were analyzed retrospectively. Venous thromboembolism events in lung cancer patients were described. The relationship between the Khorana risk score and the risk of venous thromboembolism was investigated using the cumulative incidence function with compared risk models. Results: Eight hundred fourteen lung cancer patients were included in the study. Venous thromboembolism was detected in 79 (9.7%) of the patients. Sixty one (77.2%) of the patients had pulmonary embolism, 15 (19%) had peripheral deep vein thrombosis and three (3.8%) had venous thrombosis of other sites. The cumulative incidences of venous thromboembolism for high and intermediate Khorana risk scores were 10.1% and 9.7%, respectively (p= 0.09). The cumulative incidences of venous thromboembolism at 3, 6, 12, and 24 months were 4.7%, 5.8%, 6.4%, and 9.6% for the high-grade Khorana risk score; 4.6%, 5.7%, 6.3% and 7.8% for the intermediate Khorana risk score (p= 0.11). Conclusion: The Khorana risk score was not found useful in the risk stratification of venous thromboembolism (intermediate or high risk) in patients with lung cancer. New scoring systems are needed to calculate the risk of venous thromboembolism in patients with lung cancer. © 2024 by Tuberculosis and Thorax.